REC: CardioClinics最新文献

{"title":"REC: CardioClinics 2025","authors":"Sergio Raposeiras-Roubín , Elena Díaz-Peláez , Victoria Cañadas-Godoy","doi":"10.1016/j.rccl.2026.01.003","DOIUrl":"10.1016/j.rccl.2026.01.003","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 147-151"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy of cardiac rehabilitation in older adults. A prospective cohort study","authors":"Ana Abrantes ,&nbsp;Catarina Gregório ,&nbsp;Miguel Raposo ,&nbsp;João Cravo ,&nbsp;Sofia Esteves ,&nbsp;Margarida Martins ,&nbsp;Sandra Miguel Correia ,&nbsp;Gisela Afonso ,&nbsp;Graça Araujo ,&nbsp;Pedro Alves da Silva ,&nbsp;Nelson Cunha ,&nbsp;Inês Aguiar-Ricardo ,&nbsp;Fausto J. Pinto ,&nbsp;Ana Abreu","doi":"10.1016/j.rccl.2025.10.002","DOIUrl":"10.1016/j.rccl.2025.10.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The benefits of cardiac rehabilitation (CR) in older adults are supported by limited data, with most studies showing smaller improvements compared to younger individuals. Our aim was to evaluate the efficacy of CR programs in older adults (≥65 years) compared to younger ones.</div></div><div><h3>Methods</h3><div>A single-center, prospective cohort study included consecutive patients referred to phase 2 CR, between 2017 and 2023. Participants were divided into 2 groups: older (≥65 years) and younger (&lt;65 years). Data on physical capacity, metabolic profile, and functional status were collected at baseline and after CR. The program included supervised exercise, educational sessions, dietary planning and treatment adjustments. Primary outcome was defined as improvement of at least 1<!--> <!-->mL/kg/min on peak VO₂ after program completion. Secondary outcomes included risk factor management, cardiovascular outcomes and safety.</div></div><div><h3>Results</h3><div>446 patients were included, 175 (39%) older. The primary outcome was achieved by 89 older and 168 younger patients, without statistical difference (OR, 0.36; 95%CI, 0.34–1.18). Both groups showed significant and similar improvements in aerobic physical capacity (including, VO₂ peak, percentage of predicted VO₂ reached, O₂ pulse and distance in the 6<!--> <!-->minute-walking-test), metabolic profile and New York Heart Association functional class. Major adverse cardiovascular events during a mean 2 year follow-up were similar across groups, with no safety issues reported.</div></div><div><h3>Conclusions</h3><div>CR programs were equally effective in older and younger patients, improving physical, functional, and metabolic outcomes. These findings highlight the importance of CR referrals for older adults to optimize cardiovascular health.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 87-97"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of intermittent levosimendan treatment on quality of life in advanced heart failure patients","authors":"Erwing Arturo Vargas Sáenz,&nbsp;María Fernanda Marín Betancourt,&nbsp;César Marriaga Zárate,&nbsp;William Achury Mancera","doi":"10.1016/j.rccl.2025.10.001","DOIUrl":"10.1016/j.rccl.2025.10.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Advanced heart failure (AHF) is associated with high morbidity, mortality, and impaired quality of life (QoL), now recognized as a therapeutic target. Evidence for QoL-oriented interventions in AHF remains limited. This study evaluated changes in QoL and associated factors in patients receiving intermittent outpatient levosimendan infusion.</div></div><div><h3>Methods</h3><div>We conducted a historical cohort study including patients enrolled in an outpatient levosimendan program at a national referral center for heart failure in Colombia (April 2017–March 2024). QoL was measured with the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline and after ≥3 months of therapy, with follow-up stratified by time intervals. Clinical and demographic data were retrieved from electronic records. Associations were analyzed using Wilcoxon, chi-squared, and Mann–Whitney tests.</div></div><div><h3>Results</h3><div>A total of 73 patients were included (median age 72 years; 35.6% female). Baseline median KCCQ score was 61.1. Overall, 58.9% improved in QoL, with the largest gains between 3 and 6 months. Patients with more advanced disease at baseline showed greater benefit. The most responsive domains were physical function, symptom frequency, and overall QoL. Female sex, hypertension, and moderate renal dysfunction were associated with better response.</div></div><div><h3>Conclusions</h3><div>Intermittent outpatient levosimendan infusion was associated with significant and sustained QoL improvements in AHF, particularly during the first 6 months. These findings support the potential role of prolonged therapy beyond conventional short-term regimens.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 129-136"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aneurisma congénito inferior del ventrículo izquierdo","authors":"Marta Pelaz Sánchez ,&nbsp;Antonio Rivas García ,&nbsp;Marinela Chaparro Muñoz ,&nbsp;Román Calvo Jambrina","doi":"10.1016/j.rccl.2025.09.002","DOIUrl":"10.1016/j.rccl.2025.09.002","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 160-161"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Es el sexo femenino un factor determinante y pronóstico en la evolución de la insuficiencia cardiaca?","authors":"María Anguita-Gámez,&nbsp;María Alejandra Restrepo-Córdoba,&nbsp;Josebe Goirigolzarri-Artaza","doi":"10.1016/j.rccl.2025.12.001","DOIUrl":"10.1016/j.rccl.2025.12.001","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 84-86"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Escala SOFA y mortalidad precoz tras el trasplante cardiaco urgente","authors":"Sara Martín Paniagua ,&nbsp;Alexander Stepanenko ,&nbsp;Javier Tobar Ruiz ,&nbsp;José Alberto San Román Calvar ,&nbsp;Luis de la Fuente Galán ,&nbsp;María Plaza Martín","doi":"10.1016/j.rccl.2025.03.001","DOIUrl":"10.1016/j.rccl.2025.03.001","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 155-157"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reclasificación de riesgo cardiovascular mediante ecografía vascular según el nuevo consenso en prevención primaria","authors":"Álvaro Velasco ,&nbsp;Sofía Capdeville ,&nbsp;Rocío Tello ,&nbsp;Javier Sanz ,&nbsp;Leticia Fernández-Friera ,&nbsp;Jorge Solís","doi":"10.1016/j.rccl.2025.02.005","DOIUrl":"10.1016/j.rccl.2025.02.005","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 152-154"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preferences of patients and healthcare professionals on lipid-lowering therapies for ASCVD","authors":"Rosa Fernández Olmo ,&nbsp;Ángeles Beatriz Álvarez Hermida ,&nbsp;Mar Castellanos Rodrigo ,&nbsp;Jorge Francisco Gómez Cerezo ,&nbsp;María José Igual Guaita ,&nbsp;Sergio Jesús Jansen Chaparro ,&nbsp;Juan Carlos Obaya Rebollar ,&nbsp;Javier Parrondo ,&nbsp;Laura Martín Mitjana ,&nbsp;Sonia Reimóndez-Troitiño ,&nbsp;Juan Cosín-Sales","doi":"10.1016/j.rccl.2025.08.007","DOIUrl":"10.1016/j.rccl.2025.08.007","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Controlling low-density lipoprotein cholesterol (LDL-C) levels reduces atherosclerotic risk in patients with atherosclerotic cardiovascular disease. However, not all available therapies provide the same efficacy or safety outcomes, influencing treatment preferences. Our study aimed to identify patients’ and healthcare professionals’ (HCP) preferences for the attributes related to lipid-lowering therapies (LLT).</div></div><div><h3>Methods</h3><div>A literature review and 2 focus groups (patients<!--> <!-->=<!--> <!-->4; HCP<!--> <!-->=<!--> <!-->8), were conducted to identify LLT attributes and levels. A total of 5 attributes with 2 or 3 levels each resulted in 36 scenarios. The relative importance given to each attribute was estimated using a conditional logit model.</div></div><div><h3>Results</h3><div>A total of 50 patients and 89 HCP participated. The estimated relative importance was: prevention of cardiovascular problems (HCP: 37.7%; patients: 26.8%); LDL-C reduction (HCP: 31.6%; patients: 26.8%); route and frequency of administration (HCP: 10.9%; patients: 10.3%) safety (HCP: 10.2%; patients: 24.0%); and medication collection location (HCP: 9.5%; patients: 12.1%). The preferred route and frequency of administration for HCP was a subcutaneous injection administered by an HCP once every 6 months, while patients equally preferred subcutaneous injection administered by an HCP once every 6 months and oral administration (<em>r</em> <!-->=<!--> <!-->0.01; <em>P</em> <!-->=<!--> <!-->.95) over a self-administered injection twice per month (<em>r</em> <!-->=<!--> <!-->−0.36; <em>P</em> <!-->=<!--> <!-->.01).</div></div><div><h3>Conclusions</h3><div>HCP and patients considered treatment efficacy preventing cardiovascular events and reducing LDL-C levels the most important attributes, followed by route and frequency of administration for HCP and safety for patients. Regarding route and frequency of administration, HCP preferred low frequency subcutaneous injection administered by an HCP and patients, are less prompt to accept a self-administered injection twice per month over the other options.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 98-108"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yuxtaposición izquierda de orejuelas auriculares: ¿es siempre relevante?","authors":"Diana Isabel Katekaru-Tokeshi ,&nbsp;Moisés Jiménez-Santos","doi":"10.1016/j.rccl.2025.08.001","DOIUrl":"10.1016/j.rccl.2025.08.001","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 158-159"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring comorbidities, triggers, and etiologies in heart failure. Insights from the SEPE registry subanalysis","authors":"Roberto Cristodulo ,&nbsp;Fabricio Espinoza ,&nbsp;Carlos Vaca ,&nbsp;Daniela Ureña ,&nbsp;Isabel A. Rejas ,&nbsp;Jimena Rojas ,&nbsp;Juliana Giorgi ,&nbsp;Edgardo Kaplinsky ,&nbsp;Alejandro Barbagelata","doi":"10.1016/j.rccl.2025.09.003","DOIUrl":"10.1016/j.rccl.2025.09.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Heart failure (HF) is a complex clinical syndrome characterized by a high burden of comorbidities and multiple underlying etiologies. This sub-analysis of the SEPE-Registry aimed to characterize the clinical profiles of hospitalized patients with HF and to analyze the incidence and association between etiologies, precipitating factors of decompensation and comorbidities.</div></div><div><h3>Methods</h3><div>A multicenter, cross-sectional study was conducted in Santa Cruz de la Sierra, Bolivia, including 418 patients hospitalized with a diagnosis of HF between January 2023 and April 2024.</div></div><div><h3>Results</h3><div>Hypertension was significantly associated with a higher prevalence of ischemic HF etiology (PR, 2.0; <em>P</em> <!-->=<!--> <!-->.001). Coronary artery disease was strongly associated with an ischemic etiology of HF (PR, 4.6; <em>P</em> <!-->&lt;<!--> <!-->.001). Rheumatic HF etiology demonstrated a statistically significant inverse association with comorbidity. Chagas disease was the most prevalent HF etiology in the SEPE registry and was associated with a trend toward increased cardiovascular mortality, reaching borderline statistical significance (PR, 1.3; <em>P</em> <!-->=<!--> <!-->.052). Moreover, Chagasic HF showed a significant inverse association with hypertension (PR, 0.6; <em>P</em> <!-->=<!--> <!-->.001) but a higher prevalence of pacemakers (PR, 1.7; <em>P</em> <!-->=<!--> <!-->.001). The coexistence of Chagas disease and coronary artery disease within the same HF patient was statistically significant (<em>χ</em>²: 15.0; <em>P</em> <!-->=<!--> <!-->.001) The overall cardiovascular mortality in HF patients on SEPE-HF Registry was founded as 5.5%.</div></div><div><h3>Conclusions</h3><div>HF exhibits significant clinical heterogeneity driven by the interplay between etiologies, comorbidities, and decompensating factors. The identification of distinct clinical profiles may support more personalized and effective treatment strategies.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"61 2","pages":"Pages 120-128"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}